

DAFTAR PUSTAKA

1. Korman NJ. Management of psoriasis as a systemic disease: what is the evidence. *British Journal of Dermatology*. 2020;182:840-8.
2. Amstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis a review. *Journal of American Medical Association*.2020;323:19.
3. Armenteros JMF, Arbonez XG, Sole MB, Bars AB, Novell VS, Bravo MO, dkk. Epidemiology of psoriasis a population-based study. *Actas Dermosifiliograficas*. 2019;110(5): 385-93.
4. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. *BMJ*.2020;369:1590.
5. Alverina L, Hidajat D, Hendrawan IW, Medikawati IG. Karakteristik penderita psoriasis di poliklinik rawat jalan dermatologi dan venereologi Rumah Sakit Umum Daerah Provinsi Nusa Tenggara Barat periode Januari 2016 – Desember 2020. *Intisari Sains Medis*. 2021;12(3):880-5.
6. Budianti WK, Ramadhiani M, Novianto E, Effendy EH, Soebaryo RW. Incidence and sociodermographic characteristic of allergy, autoinflammatory, and autoimmune skin disease patients in Allergy-immunology Clinic of Dermatovenereology Department of Ciptomangunkusumo General Hospital in 2014-2017. In: *Proceedings of the 23rd Regional Conference of Dermatology*. SCITEPRESS-Science and Technology Publication; 2018: 100-3.
7. Nayak PB, Girisha BS, Noronha TM. Correlation between disease severity, family income, and quality of life in psoriasis: a study from South India. *Indian Dermatology Online Journal*. 2018;9(3):165-9.
8. Affandi AM, Khan I, Saaya N. Epidemiology and clinical features of adult patients with psoriasis in Malaysia:10-year review from the Malaysian psoriasis registry (2007-2016). *Dermatology Research and Practice*. 2018;1-8.
9. Griffiths CE, Armstrong AW, Gudjonsson JE, Barker JN. Psoriasis. *The Lancet*. 2021;397:1301-15.
10. Nowowiejska J, Baran A, Flisiak I. Psoriasis and cardiometabolic disorders. *Dermatology Review*. 2020;107:508-20.
11. Hajiebrahimi M, Song C, Hagg D, Anderson TM, Villacorta L, Linder M. The occurrence of metabolic risk factors stratified by psoriasis severity: a

- Swedish population-based matched cohort study. *Clinical Epidemiology*. 2020;12;737-44.
12. Feldman SR, Hur P, Zhao Y, Tian H, Wey Z, Wang S, et al. Incidence rates of comorbidities among patients with psoriasis in the United States. *Dermatology Online Journal*. 2018;24(10):1.
 13. Pilon D, Teeple A, Zhdanova M, Ladouceur M, Cheung CH, Muser E, et al. The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. *Journal of Medical Economics*. 2019;22(2):196-203.
 14. Murniastuti DS, Danarti R. Penggunaan metotreksat pada dermatosis anak. *Media Dermato-Venereologica Indonesiana*. 2019; 46(1): 45-50.
 15. Balak DM, Gerdes S, Parodi A, Boquete LS. Long term safety of oral systemic therapies for psoriasis: a comprehensive review of the literature. *Dermatol ther*. 2020;1-25.
 16. Huang TH, Lin CF, Alalaiwe, Yang SC, Fang JY. Apoptotic or antiproliferative activity of natural products against keratinocytes for the treatment of psoriasis. *Int. J. Mol. Sci*. 2019; 20: 2558.
 17. Buhas MC, Gavliras LI, Candrea R, Catinean A, Mocan A, Miere D, Tataru A. Gut microbiota in psoriasis. *Nutrients*. 2022;14: 2970.
 18. Rauf A, Imran M, Khan IA, Rehman MU, Gilani SA, Mehmood Z, et al. Anticancer potential of kuersetin : a comprehensive review. *Phytotherapy*. 2018;1-22.
 19. Xu D, Hu MD, Wang YQ, Cui YL. Antioxidant of kuersetin and its complexes for medicinal application. *Molecules*. 2019;24:1123.
 20. Khan MS, Yusufzai SK, Kimin L, Nabila NA. Determination of chemical composition, total flavonoid content, total phenolic content, and antioxidant capacity of various crude extract of *Manihot esculata* crantz leaves. *International Journal for Research in Applied Science and Engineering Technology*. 2018;6(IV):2433-43.
 21. Hou DD, Zhang W, Gao YL, Sun Yz, Wang HX, Qi RQ, et al. Anti-inflammatory effects of kuersetin in a mouse model of MC903-induced atopic dermatitis. *International Immunopharmacology*. 2019; 74: 1-11.
 22. Yousuf M, Khan P, Shamsi A, Shahbaaz M, Hasan GM, et al. Inhibiting CDK6 activity by kuersetin is an attractive strategy for cancer therapy. *American Chemical Society*. 2020; 5; 27480-91.

23. Flores CA, Escamilla OC, Rocha EM, García CM, Cruz FJ, Montesinos GP. Association of pathogenic Th17 cells with the disease severity and its potential implication for biological treatment selection in psoriasis patients. *Mediator of Inflammation*. 2020; 1-16.
24. Li1 B, Huang L, Lv P, Li1 X, Liu1 Ge, Chen Y. The role of Th17 cells in psoriasis. *Immunology Research*. 2020;1-10.
25. Chen H, Lu C, Liu H, Wang M, Zhao, Yan Y, dkk. Kuersetin ameliorates imiquimod-induced psoriasis-like skin inflammation in mice via the NF- κ B pathway. *International Immunopharmacology*. 2017;48: 110-7.
26. Kim RM, Kim MY, Hwang HS. Kuersetin suppress CCL20 by reducing I κ B α /STAT3 phosphorylation in TNF- α /IL-17A induced HaCat cells. *J appl Biol Chem*. 2020;63(3):211-9.
27. Musa IPB, Sylviningrum, Novrial D, Salman M. Pengaruh pemberian ekstrak ciplukan (*Physalis angulata* L) terhadap jumlah fibroblast pada imiquimod-induced psoriasis mice model. *OISAA Journal of Indonesia*. 2022;5;57-65.
28. Moos S, Mohebiany AN, Waisman A, Kurchus FC. Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes. *Journal of Investigative Dermatology*. 2019;139:1110-7.
29. Irrera N, Bitto A, Vaccaro M, Mannino F, Squadrito V, Pallio G. PDRN (Polydeoxyribonucleotide), a bioactive natural compound, ameliorates imiquimod-induced psoriasis through NF- κ B pathway inhibition and Wnt/ β -Catenin Signaling Modulation. *International Journal of Molecular Science*. 2020;21:1215
30. Saka R, Jain H, Komminehi N, Chella N, Khan W. Enhanced penetration and improved therapeutic efficacy of bexarotene via topical liposomal gel in imiquimod induced psoriatic plaque model in BALB/c mice. *Journal of Drug Delivery Science and Technology*. 2020:1-11.
31. Zhou W, Hu M, Zang X, Liu Q, Du J, Hu J, et al. Luteolin attenuates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via suppression of inflammation response. *Biomedicine and Pharmacotherapy*. 2020;131:1-7.
32. Dibal NI, Garba SH, Jacks TW. Acute Toxicity of Kuersetin From Onion Skin in Mice. *Pharmaceutical and Biomedical Research*. 2020; 6(4):269-76.
33. Batiha GE, Mulla ZS, Beshbishy AM, Ikram M, Algammal AM, El-Hack EM, et al. The pharmacological activity, biochemical properties, and pharmacokinetics of the major natural polyphenolic flavonoid: Kuersetin. *Foods*. 2020; 9(374): 1-16.

34. Javanbakht S, Shaabani A. Carboxymethyl cellulose-based oral delivery systems. *International Journal of Biological Macromolecules*.2019;133: 21-9.
35. Gudjonsson JE, Elder JT. Psoriasiform disorders. In : Sewon K, Masayuki A, Anna LB, Alexander HE, David JM, Amy JM, Jeffrey SO, editors. *Fitzpatrick's Dermatology*. 9th Ed. New York: McGraw-Hill; 2019: 457-97.
36. James WD, Berger TG, Elston DM. Seborrheic dermatitis, psoriasis, recalcitrant palmoplantar eruptions, pustular dermatitis, and erythroderma. In : *Andrew's Diseases of the Skin*. Philadelphia:Elsevier; 2016: 185-98.
37. Mattozzi C, Paolino G, Richetta AG, Calvieri S. Psoriasis, vitamin D and the importance of the cutaneous barrier's integrity: An update. *J Dermatol*. 2016;43(5):507–14.
38. Choon SE, Ngim CF, Premaa S, Tey KW, Nalini MN. Clinico epidemiological profile, including body mass index of Malaysian children with psoriasis. *Med J Malaysia*. 2016;71(4): 171–6
39. Kaufman BP, Alexis AF. Psoriasis in skin of color: insights into the epidemiology, clinical presentation, Genetics, quality-of-life impact, and treatment of psoriasis in non-white racial/ethnic groups. *Am J Clin Dermatol*, 19(3):405-23.
40. Furue M, Furue K, Tsuji G, Nakahara T. Interleukin-17A and Keratinocytes in Psoriasis. *International Journal of Molecular Sciences* [Internet]. 2020 Jan 1;21(4):1275.
41. Liu A, Zhao W, Zhang B, Tu Y, Wang Q, Li Jing. Cimifugin ameliorates imiquimod-induced psoriasis by inhibiting oxidative stress and inflammation via NF- κ B/MAPK pathway. *Bioscience Reports*. 2020;40:1-11.
42. Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis: A review. *The Journal of Dermatology*. 2021;1+10.
43. Rendon A, Schakel K. Psoriasis pathogenesis and treatment. In : *Internasional Journal of Molecular Sciences*. Heidelberg:MDPI; 2019.
44. Bhutani T, Koo J, Jeon C. Evidence-Based Psoriasis. *Updates in Clinical Dermatology*. 2018;17-59.
45. Gilbert KE, Wu JJ. Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis : safety, efficacy, and patient acceptability. 2015; 65–70.
46. Novianto E, Irawan A, Wiryadi BE, Prakoeswa CRS, Kariosentono H, Roesyani IB, dkk. Alur Tata Laksana Psoriasis Vulgaris (Tipe Plak) di

- Indonesia. Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia. 2019;1-14.
47. Nowak M, Szpadel K, Jabłońska I, Pizon M, Woźniak M. Promising Strategies in Plant-Derived Treatments of Psoriasis-Update of In Vitro, In Vivo, and Clinical Trials Studies. *Molecules*. 2022;27(3):591.
 48. Cordan Y, Ünlü B, İkizoğlu G. Complementary and alternative medicine use among patients with psoriasis on different treatment regimens. *Arch Dermatol Res*. 2020;312(8):601-4.
 49. Farahnik B, Sharma D, Alban J, Sivamani R. Topical Botanical Agents for the Treatment of Psoriasis: A Systematic Review. *Am. J. Clin. Dermatol*. 2017;18:451–68.
 50. Rivera CR, Ruiz PA, Mendoza MI, Reali JR, Garcia GS, Molina GP, et al. Flavonoids Present in Propolis in the Battle against Photoaging and Psoriasis. *Antioxidants*. 2021;10(12): 2014.
 51. Bonesi M, Loizzo M, Menichini J, Tundis R. Flavonoids in Treating Psoriasis. *Immunity and Inflammation in Health and Disease*. 2018; 281-94.
 52. Singh P, Arif Y, Bajguz A, Hayat S. The role of kuersetin in plants. *Plant Physiology and Biochemistry*. 2021;166:10-19.
 53. Ulusoy HG, Sanlier N. A minireview of kuersetin: from its metabolism to possible mechanisms of its biological activities. *Critical Reviews in Food Science and Nutrition*. 2019;1-13.
 54. Tang SM, Deng XT, Zhou J, Li QP, Ge XX, Miao L. Pharmacological basis and new insight of kuersetin action in respect to its anticancer effects. *Biomedical and Pharmacotherapy*. 2020;121:1-7.
 55. Kumar R, Vijayalakshmi S and Nadanasabapathi S. Health Benefits of Kuersetin. *Defence Life Science Journal*. 2017;2(2):142-51.
 56. Asfaram A, Arabi M, Ostovan A, Sadeghi A, Ghaedi M. Simple and selective detection of kuersetin in extracts of plants and food samples by dispersivemicro-solid phase extraction based on core-shell magnetic molecularly imprinted polymers. *New J. Chem*. 2018;42:16144-53.
 57. Tao H, Zang H, Bekhit AE, Lu F. Identification and characterization of flavonoids compounds in cassava leaves (*Manihot esculenta* Crantz) by HPLC/FTICR-MS. *International Journal of Food Properties*. 2019;22(1):1134-45.

58. Jan R, Khan M, Assaf S, Lubna, Asif S, Kim KM. Bioactivity and therapeutic potential of Kaempferol and Kuersetin : New Insights for plant and human health. *Plants*. 2022;11:2623
59. Perlak MN, Szpadel K, Jablonska I, Pizon M, Wozniak M. Promising strategies in plant-derived treatment of psoriasis-update of in vitro, in vivo and clinical trial studies. *Molecules*. 2022;27:591.
60. Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. *International Journal of Molecular Sciences*. 2020;21:7488.
61. Salehi B, Machin L, Monzote L, Sharifi-Rad J, Ezzat SM, Salem MA, et al. Therapeutic Potential of Quercetin: New Insights and Perspectives for Human Health. *ACS Omega*. 2020;14(20):11849–72.
62. Oryan A, Bemani E, Bahrami S. Anti-leishmanial, immunomodulatory and anti-oxidative activity of kuersetin against cutaneous leishmaniasis caused by *Leishmania major*. *Asian Pacific Journal of Tropical Biomedicine [Internet]*. 2023;13(1):26.
63. Piovezana Bossolani GD, Silva BT, Colombo Martins Perles JV, et al. Rheumatoid arthritis induces enteric neurodegeneration and jejunal inflammation, and kuersetin promotes neuroprotective and anti-inflammatory actions. *Life Sci*. 2019; 238
64. Amjad S, Rahman MS, Pang MG. Role of Antioxidants in Alleviating Bisphenol A Toxicity. *Biomolecules*. 2020;10(8):1105.
65. Babaei, F, Mirzababaei, M., & Nassiri-Asl, M. Kuersetin in Food: Possible Mechanisms of Its Effect on Memory. *Journal of Food Science*. 2018.
66. Kawaguchi K, Kaneko M, Miyake R, Takimoto H, Kumazawa Y. Potent Inhibitory Effects of Kuersetin on Inflammatory Responses of Collagen-Induced Arthritis in Mice. *EndocrMetab Immune Disord Drug Targets* 2019; 19(3): 308-15.
67. Yang Y, Zhang X, Xu M, Wu X, Zhao F, Zhao C. Kuersetin attenuates collagen-induced arthritis by restoration of Th17/Treg balance and activation of Heme Oxygenase 1 mediated anti-inflammatory effect. *Int Immunopharmacol*. 2018;153-62.
68. Chekalina N, Burmak Y, Petrov Y, Borisova Z, Manusha Y, Kazakov Y, et al. Kuersetin reduces the transcriptional activity of NF- κ B in stable coronary artery disease. *Indian Heart Journal*. 2021;70(5):593–7.

69. Hosseini A, Razavi BM, Banach M, Hosseinzadeh H. Kuersetin and metabolic syndrome: A review. *Phytotherapy Research*. 2021 Jun 8;35(10):5352–64.
70. Sharma, S. Kumar, M. Sharma, N. Upadhyay, S. Kumar, Z. Ahmed, N. Mahindroo, Anti-Diabetic Anti-oxidant and anti-adipogenic potential of kuersetin rich ethyl acetate fraction of *Prunus persica*. *Pharmacogn. J.*2018; 463-9.
71. Shi GJ, Li Y, Cao QH, Wu HX, Tang XY, Gao XH, et al. In vitro and in vivo evidence that kuersetin protects against diabetes and its complications: A systematic review of the literature. *Biomedicine & Pharmacotherapy*. 2019 ;109:1085–99.
72. Cunningham P, Patton E, VanderVeen BN, Unger C, Al-Adhami A, Enos RT, et al. Sub-chronic oral toxicity screening of kuersetin in mice. *BMC Complementary Medicine and Therapies*. 2022;22(1);23.



